Reactions 1680, p194 - 2 Dec 2017 Diarrhoea: case report A 19-year-old man developed significant diarrhoea while receiving sorafenib and irinotecan for unresponsive renal masses [routes, dosages, duration of treatments to reaction onset and outcome not stated]. He subsequently died secondary to multisystem failure. The man was hospitalised because of a renal neoplasm. Following examinations, he underwent a radical tumour nephrectomy. After further examination, a diagnosis of TFE-3 translocation-associated renal cell carcinoma was made. He was initially treated with AREN0321 chemotherapy regimen for high risk renal tumours comprised cyclophosphamide, doxorubicin, vincristine and carboplatin, along with palliative radiation therapy but he developed disease progression. Consequently, the regimen was changed to COG protocol involving vincristine and irinotecan but no significant response was obtained. Hence, He started receiving a combination regimen of sorafenib and irinotecan which resulted in stable disease for nearly 8 weeks, but he experienced significant diarrhea. The man was advised to discontinue sorafenib and the treatment was changed to a combination of irinotecan, temsirolimus, and bevacizumab. Although, PET scan was negative, clinically progressive disease was developed under treatment and he died secondary to multisystem failure. Author comment: "It was decided to start the patient on a combination regimen consisting of Sorafenib plus Irinotecan. This combination resulted in stable disease for approximately 8 weeks. However, this combination caused significant diarrh[o]ea, and Sorafenib was stopped." Nelius T, et al. TFE3 translocation-associated renal cell carcinoma presenting as avascular necrosis of the femur in a 19-year-old patient: Case report and review of the literature. Case Reports in Medicine 2011: 14 Jul 2011. Available from: URL: http://doi.org/10.1155/2011/432917 - USA 803283898 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera